Skip to main content
Terug
ONC logo

BeOne Medicines Ltd.

Datakwaliteit: 100%
Oversold
ONC
NASDAQ Healthcare Medical - Pharmaceuticals
€ 275,69
▲ € 0,96 (0,35%)
Marktkapitalisatie: 29,46B
Dagbereik
€ 271,47 € 276,98
52-Weeksbereik
€ 196,45 € 385,22
Volume
203.033
50D / 200D Gem.
€ 329,69 / € 314,04
Vorige Slotkoers
€ 274,73

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 102,7 0,4
P/B 6,8 2,9
ROE % 7,5 3,7
Net Margin % 5,4 3,9
Rev Growth 5Y % 46,0 10,0
D/E 0,5 0,2

Koersdoel Analisten

Hold
€ 409,67 +48.6%
Low: € 394,00 High: € 425,00
Forward K/W
45,2
Forward WPA
€ 6,08
WPA Groei (sch.)
+0,0%
Omzet Sch.
6,4 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 19,49
€ 18,53 – € 20,81
10 B 4
FY2029 € 16,17
€ 15,38 – € 17,26
9,3 B 4
FY2028 € 12,93
€ 8,18 – € 18,18
8,3 B 10

Belangrijkste Punten

Revenue grew 45,99% annually over 5 years — strong growth
Debt/Equity of 0,46 — conservative balance sheet
Generating 941,74M in free cash flow
P/E of 102,67 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 5,76%
Cash machine — converts 328,21% of earnings into free cash flow

Groei

Revenue Growth (5Y)
45,99%
Revenue (1Y)40,23%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
7,46%
ROIC5,27%
Net Margin5,37%
Op. Margin8,37%

Veiligheid

Debt / Equity
0,46
Current Ratio3,41
Interest Coverage7,68

Waardering

P/E Ratio
102,67
P/B Ratio6,75
EV/EBITDA60,19
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 40,23% Revenue Growth (3Y) 47,41%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 45,99% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,34B Net Income (TTM) 286,93M
ROE 7,46% ROA 3,50%
Gross Margin 87,49% Operating Margin 8,37%
Net Margin 5,37% Free Cash Flow (TTM) 941,74M
ROIC 5,27% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,46 Current Ratio 3,41
Interest Coverage 7,68 Dividend Yield 0,00%
Valuation
P/E Ratio 102,67 P/B Ratio 6,75
P/S Ratio 5,51 PEG Ratio -0,18
EV/EBITDA 60,19 Dividend Yield 0,00%
Market Cap 29,46B Enterprise Value 26,91B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,34B 3,81B 2,46B 1,42B 1,18B
Net Income 286,93M -644,79M -881,71M -2,00B -1,46B
EPS (Diluted) 32,89 -6,12 -8,45 -19,37 -15,21
Gross Profit 4,67B 3,22B 2,08B 1,13B 1,01B
Operating Income 447,14M -568,20M -1,21B -1,79B -1,44B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,19B 5,92B 5,81B 6,38B 8,54B
Total Liabilities 3,83B 2,59B 2,27B 2,00B 2,40B
Shareholders' Equity 4,36B 3,33B 3,54B 4,38B 6,13B
Total Debt 2,00B 1,08B 930,19M 596,68M 694,64M
Cash & Equivalents 4,55B 2,63B 3,17B 3,87B 4,38B
Current Assets 6,23B 3,99B 4,20B 5,21B 7,61B
Current Liabilities 1,83B 2,21B 1,81B 1,47B 1,60B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#391 of 1052
51

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026